Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more
Market Cap & Net Worth: Exact Therapeutics AS (EXTX)
Exact Therapeutics AS (OL:EXTX) has a market capitalization of $12.44 Million (Nkr141.71 Million) as of March 19, 2026. Listed on the OL stock exchange, this Norway-based company holds position #32815 globally and #199 in its home market, demonstrating a 28.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Exact Therapeutics AS's stock price Nkr2.24 by its total outstanding shares 63263347 (63.26 Million).
Exact Therapeutics AS Market Cap History: 2020 to 2026
Exact Therapeutics AS's market capitalization history from 2020 to 2026. Data shows change from $163.80 Million to $12.44 Million (-37.34% CAGR).
Exact Therapeutics AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Exact Therapeutics AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EXTX by Market Capitalization
Companies near Exact Therapeutics AS in the global market cap rankings as of March 19, 2026.
Key companies related to Exact Therapeutics AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Exact Therapeutics AS Historical Marketcap From 2020 to 2026
Between 2020 and today, Exact Therapeutics AS's market cap moved from $163.80 Million to $ 12.44 Million, with a yearly change of -37.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr12.44 Million | +62.32% |
| 2025 | Nkr7.66 Million | -63.30% |
| 2024 | Nkr20.88 Million | -68.67% |
| 2023 | Nkr66.63 Million | 0.00% |
| 2022 | Nkr66.63 Million | -31.03% |
| 2021 | Nkr96.61 Million | -41.02% |
| 2020 | Nkr163.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Exact Therapeutics AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.44 Million USD |
| MoneyControl | $12.44 Million USD |
| MarketWatch | $12.44 Million USD |
| marketcap.company | $12.44 Million USD |
| Reuters | $12.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.